What is MS Phase 3 Fingolimod TRANSFORMS?
CATEGORY:
TYPES:Generic: Fingolimod Clinical Trial
NCT00340834 is a completed 12-month double-blind, randomized study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod administered orally once daily versus interferon ß-1a administered IM once weekly in patients with relapsing-remitting MS. Other study ID #CFTY720D2302.
Save up to 80% off your prescriptions!
How do members experience MS Phase 3 Fingolimod TRANSFORMS?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 10 | 12 | |
| Amyotrophic lateral sclerosis | 1 | 2 | |
| Participate in clinical trial | 1 | 4 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Elevated blood pressure | 1 | |
| Hair loss | 1 | |
| Heart rate low (bradycardia) | 1 | |
| Low white blood cell count (leukopenia) | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 2 | |
| Mild | 5 | |
| None | 7 |
Member evaluations
TickledPink
evaluated on Apr 06, 2010
- Perceived effectiveness for multiple sclerosis: Major
- Side effects: Mild
Learn more about our community’s experience with MS Phase 3 Fingolimod TRANSFORMS
What are people saying about MS Phase 3 Fingolimod TRANSFORMS?
14
14
members have reported taking MS Phase 3 Fingolimod TRANSFORMS
Join the conversation and connect with people who have taken MS Phase 3 Fingolimod TRANSFORMS
Last updated: